U.S. Licensing Regulation as a Model for Developing Countries Benton Martin Emory University School of Law Juris Doctor Candidate 2010.

Slides:



Advertisements
Similar presentations
The Federal Technology Transfer Process: Licenses and Cooperative Research and Development Agreements ADVANCED LICENSING INSTITUTE AT.
Advertisements

Managing Intellectual Property Assets in International Business Anil Sinha, Counsellor, SMEs Division World Intellectual Property Organization (WIPO)
POLICY IMPLICATIONS OF NEW TRENDS IN TECHNOLOGY TRANSFER John H. Barton
By Joseph P. Allen 2014 AUTM Eastern Regional Meeting.
Technology and Economic Development Intellectual Property Issues in Research Jim Baker Director Office of Technology and Economic Development
Intellectual Property Rights Regulations in Russia: Case of Government-Supported R&D Irina Dezhina Leading Researcher, Ph.D. Institute for the Economy.
CONFIDENTIAL © 2012 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is confidential, proprietary and the property of.
IP Issues in Research Jim Baker, Executive Director Innovation, and Industry Engagement.
Working Together to Improve Global Health
Air Force Materiel Command I n t e g r i t y - S e r v i c e - E x c e l l e n c e Developing, Fielding, and Sustaining America’s Aerospace Force INTELLECTUAL.
Public Norms and Private Ordering: The Contractual Creation of a Biomedical Research Commons Prof. Peter Lee UC Davis School of Law October 4, 2008 Prof.
Technology Transfer and Industry Sponsored Research Challenges Prepared for Karina Edmonds May 27, 2010 Technology Transfer and Intellectual Property Management.
February 25, 2014 SERIES 4, SESSION 2 OF AAPLS APPLICANTS & ADMINISTRATORS PREAWARD LUNCHEON SERIES Material Transfer and Confidentiality Agreements.
Main Legal Aspects of the Choice of TTO Model N.Romanova Saratov State University named after N.G.Chernyshevsky.
Vilnius Lithuania BSc.: Biochemistry Neuropsychology J.D.: University of Oregon LL.M.:University College London Pacific Northwest National Laboratory.
Intellectual Property: Kenneth Kirkland, Ph.D. Executive Director, Iowa State University Research Foundation (ISURF) Director, Office of Intellectual Property.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
Safeguarding the Public Interest with NIH and EU Research Funding Sandeep P. Kishore Universities Allied for Essential Medicines Young Professionals Chronic.
Cern.ch/knowledgetransfer. Knowledge Transfer | Accelerating Innovation Charlyne Rabe CONTRACTS FOR TECHNOLOGY TRANSFER Charlyne RABE KT Legal Advisor.
The Issue of Technology Readiness Level One of the current issues being discussed by the Department of Energy’s Technology Transfer Working Group is the.
Working With Federal Laboratories Tim Wittig Principal Technology Management Group SAIC 202/
Technology Transfer at Rice
INDUSTRY SPONSORED RESEARCH David Erem University of Kentucky Office of Sponsored Programs.
Tech Launch Arizona Tech Transfer Arizona Rakhi Gibbons, Asst. Director for Biomedical and Life Sciences Licensing.
Sources of Support and What They Mean to the Field Dr. Duff Gillespie June 15 th, 2002 Africa SOTA, Nairobi.
Overview of the Indian Eqvt. to Bayh-Dole Act (USA) [Protection and Utilization of Public Funded Intellectual property (Bill 2008)]. By Dr. Gopakumar G.
Researchers’ Consulting Activities FITT (Fostering Interregional Exchange in ICT Technology Transfer)
Session 4: The Convention on Biological Diversity Making Access Decisions.
Government Funded Inventions Mark L. Rohrbaugh, Ph.D., J.D. Acting Director Office of Technology Transfer National Institutes of Health.
NIH Funding Recipient Responsibilities February, 2004 Office of Technology Transfer Office of the Director National Institutes of Health.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
1Managed by UT-Battelle for the U.S. Department of Energy ITS America May 2010 Technology Transfer Follows Many Pathways: “It’s a Contact Sport” Work for.
Intellectual Property Alignment of Current Policies Tana Pistorius UNISA Government CIO Summit Towards reducing costs of doing business in government and.
1 Chapter 33 International business Copyright © Nelson Australia Pty Ltd 2003.
Commons, Networks, and Technology Transfer Gerald Barnett Director, Intellectual Property Management University of California, Santa Cruz.
Getronics Government Solutions National Aeronautics and Space Administration Turning Goals Into Reality 2001 Conference Technology Commercialization Do.
Privatizing the intellectual commons: Universities and the commercialization of biotechnology Nicholas S. Argyres Senior Associate Dean-Faculty and Vernon.
Overview of the Indian Eqvt. to Bayh-Dole Act (USA) [Protection and Utilization of Public Funded Intellectual property (Bill 2008)]. By Dr. Gopakumar G.
“IP Universities” Istanbul, April 14 to 15, 2011 Albert Long Hall, BOGAZICI UNIVERSITY The U.S. Bayh- Dole Act Av. Uğur Aktekin The U.S. Bayh-
POLICY INCENTIVES FOR INTELLECTUAL PROPERTY DEVELOPMENT PEREZ W.J ODERO LEGAL CONSULTANT 5 TH JUNE 2005.
Pro Software Patentability Katie Jones Emma Boston Rodney Ezzard Alfred Williams Katie Jones Emma Boston Rodney Ezzard Alfred Williams.
Biotechnology / Life Sciences Ensuring Access Christina Sampogna July 2005 CASRIP – University of Washington, Seattle *Views expressed are those of the.
Academic Technology Transfer Operations and Practice Knowledge Economy Forum IV Istanbul, Turkey March 22-25, 2005 Alistair Brett Oxford Innovation.
Berkeley Lab Partnerships with Industry Betsy Quayle Contracts Officer Berkeley Lab Innovation and Partnerships Office.
1 Some Risks Associated With Research and Development Under Federal Government Contracts Charles R. “Rod” Marvin, Jr., Esq. Venable, LLP Washington, DC.
Intellectual Property Right Bernard Denis, DG-KTT.
NATIONAL CONFERENCE Intellectual Property Policies for Universities and Innovation dr. sc. Vlatka Petrović Head, Technology Transfer Office Acting Head,
Policy on the Management of Intellectual Property in Technology Transfer Activities at CERN CERN/FC/5434/RA Technology Transfer Network Meeting – 10 th.
Top 10 Legal Minefields A University Perspective October 8, 2009 Catherine Shea Associate University Counsel University of Colorado.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
Technology Transfer in The United States Paul Zielinski Director, Technology Partnerships Office, National Institute of Standards and Technology Chair,
International Business Environments & Operations
Review of Research-Related Agreements Between Academic Institutions and Other Entities. Manoja Ratnayake Lecamwasam, PhD Intellectual Property and Innovation.
Intellectual Property And Data Rights Issues Domestic & Global Perspectives Bayh-Dole act -- rights in data Henry N. Wixon Chief Counsel National Institute.
Global Technology Transfer and Commercialization: Policies and Instruments Dr. Didier Kane The University of Texas at Austin (USA) IC² Institute – Global.
Technology Transfer Office
Technology Transfer at SSC Atlantic
Technology Transfer Office
IP-INITIAL® द्वारा प्रस्तुत IP-INITIAL®
Towards a roadmap for collaborative R&D
Financing Small Firm Innovation in the United States
Universities and the Commercial World
Partnering with Business and Industry
Jakob Wested and Helen Yu and Timo Minssen
The Bayh–Dole Act: Where Are We Today?
U.S. Army Technology Transfer Mechanisms
Presentation transcript:

U.S. Licensing Regulation as a Model for Developing Countries Benton Martin Emory University School of Law Juris Doctor Candidate 2010

Reason for Legislation Prior to Bayh-Dole: “the U.S. government owned approximately 28,000 patents, [but] less than 4 percent were licensed to industry.” Now: Licensing of government funded inventions has substantially increased post-Bayh-Dole Critics: argue that licensing would have increased even without Bayh-Dole  BUT: agree that Bayh-Dole “accelerated this growth by clarifying ownership rules, by making these activities bureaucratically easier to administer, and by changing norms toward patenting and licensing at universities.”

Needed in Developing Countries? Some scholars say NO- costs outweigh the benefits for developing countries Others say clarification of ownership should be emulated  But cautions that legislation must move beyond clarification to create socially beneficial national IP legislation Countries will likely continue to adopt Bayh-Dole like provisions due to its apparent success in the U.S.  China, South Africa, Brazil, Malaysia

U.S. Tech Transfer Regulations Stevenson-Wydler Technology Innovation Act of 1980 :  Required government owned and operated laboratory (GOGOs) involvement in technology transfer Bayh-Dole Act of 1980:  Allowed universities and small businesses to take title to inventions generated using federal funds Federal Technology Transfer Act of 1986:  Allowed government labs to enter into CRADAs. Recent Legislation:  Guarantees CRADA collaborator a license of their choosing  Requires Commercial Development Plan See National Technology Transfer and Advancement Act of 1995 & Technology Transfer Commercialization Act of 2000

Key Aspects of GOGO Tech Transfer compared to Universities Cooperative Research and Development Agreements (CRADAs): made in advance of invention and gives companies:  Purpose of lessening negotiation time needed for collaborations  Gives right to choose to enter into an exclusive or non- exclusive license  Ability to provide supplemental funds to federal projects Commercial Development Plans: Licensees must have a plan to bring the technology to practical application. Failure to take reasonable effort to follow the plan and result in canceling the license. Cannot Spin Off Start-up Companies

Key Aspects of Both No Research Exemptions: Neither law requires license exemptions for use in research of new inventions. See also Madey v. Duke University, 307 F.3d 1351, 1362 (Fed. Cir. 2002). Preference for Domestic Manufacturing and Small Businesses: Both laws express preference for small businesses and domestic manufacturing-licensees exhibiting these characteristics are given priority Access Provisions :  “March-in” Rights: Allows government to force the licensing of a technology to a licensee of its choosing if original licensee is not acting in the public’s interest  “Exceptional Circumstances”: Allows government to retain title in “exceptional circumstances” if it will promote the government’s objectives

Addressing Needs in Developing Countries “appropriate policy options will depend on regional, national and sectoral analyses of conditions and objectives” Sara Boettiger & Alan Bennett, The Bayh- Dole Act: Implications for Developing Countries, 46 IDEA 261, 262 (2006).

Positive Aspects of US Law for Developing Countries Clarity of ownership accelerates economic growth CRADAs have been successful in reducing negotiation costs Commercial Development Plans create transparency and allow for specialized licensing Domestic/Small Business Preference

Negative Aspects of US Law for Developing Countries Conservation of public domain Cost of establishing TTO system Lack of even a limited Research Exemption “March-in” Rights create uncertainty, yet haven’t proven to be useful

Aspects That May Need Modification “Domestic Manufacturing” preference may need to be changed to a “Domestic Benefit” requirement Must have clear and effective provision for access to essential medicines

Solution to Low Resources: Regional, rather than Institutional, Tech Transfer Approach uses regional or technology specific tech transfer offices (TTOs) rather than universities Pro : Addresses Problems of:  Scarcity of IP experts in developing countries  High cost of maintaining TTOs  Competing Patents causing Anti-commons Con : neglects non-patent management functions of institutional TTOs

Encouraging PPPs

Public-Private Partnerships Purpose : to improve access to immunization for children in impoverished countries Mechanisms : Innovative funding, partnerships, and technologies Important Partners :  Governments and vaccine industry of industrialized countries  Governments and vaccine industry of developing countries  World Health Organization, WHO  United Nations Children's Fund, UNICEF  The World Bank Group  Bill & Melinda Gates Foundation  Research institutes  Non-governmental organizations  Foundations  Technical health institutes For more information see

Solutions: Use of CRADAs to Allow Public-Private Involvement in Research PPPs like GAVI could use CRADAs to provide resources to research in exchange for increased control over the licensing of the resulting technology Pros : provides a possible mechanism to address neglected diseases Cons : may be used by corporations to gain exclusive licenses on technology  Could be addressed by careful regulation drafting

Access to Medicines

Solutions: “Open Licensing” Like free software licensing, this approach uses propriety rights to secure freedom for an open class of potential users. Pros: allows generic competitors to use the technology in developing markets, driving the price down Cons: lowers the value of granted license rights

Solutions: Research Institution Determines the License Type This approach give the research institution complete control over whether a license is non-exclusive or exclusive Pros : Allows discretion in limiting the amount of exclusive licenses Con : Discourages industry from licensing technologies due to heavy regulation of contract negotiation

Solutions: “Commercial Development Plan” (CDP) Tailored to Ensure Access Approach 1: Requiring licensing language that reserves rights for the research institution to use the technology for humanitarian purposes  Effect: Decreases the value of licensed patent rights, especially when the major market for the technology is humanitarian Approach 2: Require CDP to address humanitarian uses.  Effect: Gives licensee full rights but provides mechanism to keep them accountable Developed by Public Intellectual Property Resource for Agriculture and Universities Allied for Essential Medicines. See Michael S. Mireles, The Bayh-Dole Act and Incentives for the Commercialization of Government-Funded Invention in Developing Countries, 76 UMKC L. Rev. 525, (2007).

Solutions: Limited Research Exemption within the Legislation One suggestion is to require that all researchers supported by federal funding get a royalty-free license to use other technology than resulted from federal funding Pros :  Limits potential for anti-commons effect  Is less drastic than a complete research exemption Con : Any research exemption has some effect on the value of the licensed patent rights

Questions?